OBI Pharma, Inc. (4174.TWO)

TWD 58.3

(-2.18%)

Market Cap (In TWD)

14.94 Billion

Revenue (In TWD)

41.54 Million

Net Income (In TWD)

-1.04 Billion

Avg. Volume

2.73 Million

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
58.0-92.9
PE
-
EPS
-
Beta Value
0.936
ISIN
TW0004174008
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Heidi Wang Ph.D.
Employee Count
-
Website
https://www.obipharma.com
Ipo Date
2012-12-12
Details
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.